Homology Medicines have received clearance from Health Canada to initiate the juMPStart trial for HMI-203, a one-time, in vivo gene therapy candidate for the treatment of adults with Hunter Syndrome (MPS II).
If you are interested in knowing more, join Homology Medicines’ juMPStart clinical trial educational webinar:
Tuesday, September 20 at 8:00 p.m. ET
The webinar will review details about Homology’s
investigational gene therapy – HMI-203 – and the
ongoing Phase 1 juMPStart clinical trial for adults.
To RSVP, please email
Read the report: